Home

Ascendis Pharma

Ascendis Pharma We apply our TransCon technology platform to build a leading, fully integrated biopharma company & make a meaningful difference for patients, caregivers & HCPs. DENMARK UNITED STATES Investors & New June 11, 2021. Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency. May 28, 2021. Ascendis Pharma A/S Invites the Public to Attend A Story of Courage: Living with Hypoparathyroidism in Support of World Hypopara Awareness.

Ascendis Pharma: We've got making a difference for

Ascendis Pharma was founded in 2007 based on the innovative TransCon technology platform. We are headquartered in Copenhagen, Denmark and are publicly traded, following an initial public offering in 2015 (Nasdaq: ASND). We have employees working across the globe to improve patients' lives. Our offices and research sites are in Route to market: Pharmacies, private hospitals, dispensing doctors, government. Brands: Pharmachem, Reuterina, Sinucon, Clonam, Phlexy, Surgical Innovations, RCA, The. Ascendis Pharma is proud to be an equal opportunity workplace and we believe that diversity and inclusion among our workforce is critical to our success as a global company. Individuals seeking employment at Ascendis Pharma are considered without regards to age, ancestry, color, gender (including pregnancy, childbirth, or related medical. As of March 31, 2021, Ascendis Pharma had cash, cash equivalents and marketable securities of €771.1 million compared to €834.1 million as of December 31, 2020. As of March 31, 2021, Ascendis. Achondroplasia is a skeletal disease and the most common form of dwarfism. Those living with the condition may experience severe skeletal complications and comorbidities. Abnormal skeletal development can lead to sleep apnea, chronic back and leg pain from lower spine impingement and sudden infant death from cervical compression

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives About Ascendis Pharma A/S Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon™ technologies to create new and. By clicking I consent, you agree that you reside in the U.S. and are at least 18 years old and consent to receive tailored communication via the email address you provide, including providing educational and marketing information from Ascendis Pharma A/S, Ascendis Pharma, Inc. and Ascendis Pharma Endocrinology, Inc., such as newsletters and updates, and to be contacted for your opinions.

Ascendis Pharma A/S currently has an average rating of Buy and an average target price of $192.43. Shares of Ascendis Pharma A/S stock opened at $131.55 on Thursday. The firm has a fifty day simple moving average of $135.21. The company has a market cap of $7.08 billion, a P/E ratio of -13.95 and a beta of 0.76. Ascendis Pharma A/S has a 52. COVID-19 Corona Virus South African Resource Portal - sacoronavirus.co.za Home; About us. Our people. Executive Management; Senior Leadership EU & RSA; Governanc Ascendis Pharma Home - Ascendis Pharma DK Vi anvender vores TransCon teknologiplatform til at opbygge en førende, fuldt integreret biofarmaceutisk virksomhed og gøre en meningsfuld forskel for patienter, plejepersonale og ansatte i sundhedsvæsenet Pharma Ascendis Health Pharma Companies/Brands: A business unit with a world-class regulatory team. The team has been held up by independent consultants as the benchmark for Pharmaceutical Regulatory teams. Development and manufacture of pharmaceutical products since 1986

Ascendis Pharma (650) 374-6343 tle@ascendispharma.com Media contact: Ron Rogers Ascendis Pharma (650) 507-5208 rrs@ascendispharma.com Patti Bank Westwicke Partners (415) 513-1284 patti.bank@westwicke.com ir@ascendispharma.co Animal Health: Soné Briers sone.briers@ascendishealth.com; 012 346 2095; Consumer Brands: Odille Bielderman odille.bielderman@ascendishealth.com 011 036 9519 Charlene Du Toit charlene.dutoit@ascendishealth.com; 011 036 9432; Pharma: Karen Scholtz karen.scholtz@ascendishealth.com; 011 036 9570; Medical: Chris Swanepoel chriss@ascendismedical.com 011 568 904 Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to September 25, 2021. COPENHAGEN, Denmark, June 11, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, today announced that the U.S.

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies Ascendis Pharma (NASDAQ:ASND) announced late of Friday that the U.S. FDA has extended the review period for the company's lonapegsomatropin Biologics License Application (BLA). The health. Ascendis, is a health and wellness company founded in 2008 ad listed in the healthcare sector of the JSE.. This platforms is brought to you by Ascendis Pharma (Pty) Ltd and Ascendis Consumer brands. The Pharmaceutical division is a well-established, key player within the South African healthcare sector (Private, Dispensing and Public); with several strategic partnerships to increase the. Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using our innovative TransCon prodrug technology platform, we continue to identify new opportunities addressing areas of high unmet medical need

Ascendis Pharma is a biotechnology company applying its innovative prodrug technology to build a leading, fully integrated rare disease company. Our science-driven and passionate people are. Ascendis Pharma A/S (NASDAQ:ASND) Q1 2021 Earnings Call May 27, 2021, 4:30 p.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Ladies and.

Ascendis Pharma A/S Announces Results of Phase 1 Study of

  1. Ascendis Pharma is a European biopharma concern with a market disruptive technology called TransCon that is able to convert any drug into a sustained or extended release molecule without increase.
  2. Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth.
  3. Earnings And Revenue Ascendis Pharma's per-share loss will be near $1.84 on sales of $2.00 million, according to Wall Street analysts. In the same quarter last year, Ascendis Pharma announced EPS.
  4. Ascendis Pharma A/S (NASDAQ:ASND) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for ASND is 66.6. Stocks with.
  5. Ascendis Pharma stock is on the move today because pivotal trial results comparing a weekly injection of the company's lead candidate, TransCon HGH, suggest it's as good or better than daily.

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates and one oncology product candidate in clinical development. The company continues to. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon™ technologies to create new and potentially best-in-class therapies

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America. Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, May 26th. The biotechnology company reported ($1.17) earnings per share for the quarter, beating analysts' consensus estimates of ($2.06) by $0.89. Ascendis Pharma A/S had a negative net margin of 7,700.88% and a negative return on equity of 54.80%

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus Ascendis Pharma A/S (NASDAQ:ASND) - Analysts at Wedbush lowered their Q2 2021 EPS estimates for shares of Ascendis Pharma A/S in a research report issued to clients and investors on Monday, June 14th. Wedbush analyst L. Moussatos now forecasts that the biotechnology company will post earnings o --Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced an equity.

Ascendis Pharma Bone Diseases A/S is located in Hellerup, Hovedstaden, Denmark and is part of the Pharmaceutical Manufacturing Industry. Ascendis Pharma Bone Diseases A/S has 16 total employees across all of its locations and generates $377,291 in sales (USD). There are 8 companies in the Ascendis Pharma Bone Diseases A/S corporate family Ascendis Pharma A/S: Redwood City, CA: Senior Scientist, QC: Ascendis Pharma A/S: Redwood City, CA: Associate Director, Medical Writing: Ascendis Pharma A/S: Palo Alto, CA: $111K-$224K: Manager, Medical Writing: Ascendis Pharma A/S: Palo Alto, CA: Associate Director, Regulatory Affairs: Ascendis Pharma A/S: Redwood City, CA: $107K-$208K: Front. Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm.

About Us - Ascendis Pharma U

  1. --Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the.
  2. The FDA has extended the ongoing review of the marketing application of Ascendis Pharma A/S's (NASDAQ: ASND) TransCon hGH (lonapegsomatropin) for the treatment of pediatric growth hormone.
  3. Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the.
  4. Find out what works well at Ascendis Pharma from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular roles and read about the team's work-life balance. Uncover why Ascendis Pharma is the best company for you
  5. About Ascendis Pharma A/S Ascendis Pharma A/S manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous.
  6. Ascendis Health is a South African-based health and wellbeing company which owns a portfolio of market-leading brands for people, plants and animals. Ascendis Health owns some of the most highly recognised brands in the health and care market in South Africa. Owing to its high end market positioning certain brands are price setters rather than.

10 brokers have issued 1-year price objectives for Ascendis Pharma A/S's shares. Their forecasts range from $178.00 to $216.00. On average, they anticipate Ascendis Pharma A/S's stock price to reach $192.43 in the next twelve months. This suggests a possible upside of 43.8% from the stock's current price Ascendis Pharma has raised a total of $85.7M in funding over 3 rounds. Their latest funding was raised on Jan 1, 2017 from a Post-IPO Equity round. Ascendis Pharma is registered under the ticker NASDAQ:ASND . Their stock opened with $18.00 in its Jan 28, 2015 IPO. Ascendis Pharma is funded by 9 investors Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006. High-Paying Jobs at Ascendis Pharma A/S. IT Manager, Foundational Technologies. $200K — $250K *. Ascendis Pharma A/S • Palo Alto, CA 94301. 4 days ago. Associate Director, Corporate & G&A FP&A.

Ascendis Pharma A/S (NASDAQ:ASND) Q1 2021 Earnings Conference Call May 27, 2021 4:30 PM ET. Company Participants. Scott Smith - Senior Vice President & Chief Financial Officer. Jan Mikkelsen. The analysts are definitely expecting Ascendis Pharma's growth to accelerate, with the forecast 5x growth ranking favourably alongside historical growth of 21% per annum over the past five years

Ascendis Divisions Pharma-Me

  1. Market capitalization of Ascendis Pharma (ASND) Market cap: $7.58 B As of June 2021 Ascendis Pharma has a market cap of $7.58 B.This makes Ascendis Pharma the world's 1819th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to mesure.
  2. Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference Globe Newswire 11/25 07:05 ET--Analyst Actions: Wedbush Adjusts Price Target on Ascendis Pharma A/S to $209 From $206, Keeps Outperform Rating MT Newswires 11/16 10:13 ET
  3. Ascendis Pharma A/S (NASDAQ:ASND) Q3 2020 Earnings Call Nov 11, 2020, 4:30 p.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Ladies and.
  4. Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia
  5. COPENHAGEN, Denmark, May 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ: ASND ), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live webcast on Thursday, May 27, 2021 at 4.
  6. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. ©April 2019 Ascendis Pharma A/S. Company Overview 3 • Create best-in-class products addressing unmet medical needs by applyin
  7. Ascendis Pharma Endocrinology Division A/S is located in Hellerup, Hovedstaden, Denmark and is part of the Pharmaceutical Manufacturing Industry. Ascendis Pharma Endocrinology Division A/S has 16 total employees across all of its locations and generates $424,640 in sales (USD)

Careers - Ascendis Pharma U

Ascendis Pharma Investigational Site: Oslo, Norway, 0176 : Sponsors and Collaborators. Ascendis Pharma A/S. Investigators. Layout table for investigator information; Study Director: David B Karpf, MD: Ascendis Pharma A/S North American Medical Monitor/Medical Expert: Study Director Ascendis Pharma A/S had a negative return on equity of 54.80% and a negative net margin of 7,700.88%. Several brokerages have weighed in on ASND. Canaccord Genuity upped their price target on Ascendis Pharma A/S from $190.00 to $196.00 and gave the stock a buy rating in a report on Tuesday, June 1st. Credit Suisse Group upped their price. Ascendis Pharma has filed to run a clinical trial of an intratumoral, sustained-release formulation of resiquimod. The TLR agonist has shown preclinical promise as a cancer therapy, but its. Ascendis Pharma A/S - ADR () Stock Market info Recommendations: Buy or sell Ascendis Pharma A/S - ADR stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Ascendis Pharma A/S - ADR share forecasts, stock quote and buy / sell signals below.According to present data Ascendis Pharma A/S - ADR's ASND shares and potentially its market environment have been in. Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months. Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates. What 5 Analyst Ratings Have To Say About Ascendis Pharma

The Investment Case For Ascendis Pharma - Ascendis PharmaTransCon hGH - Ascendis Pharma

Ascendis Pharma A/S (ASND) Stock Price, News, Quote

  1. Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,..
  2. View Ascendis Pharma AS ASND investment & stock information. Get the latest Ascendis Pharma AS ASND detailed stock quotes, stock data, Real-Time ECN, charts, stats and more
  3. Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology

Disclaimer. Ascendis Pharma A/S published this content on 06 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 July 2021 12:33:06 UTC 07 Jan 2021 National Medical Products Administration (NMPA) approves IND application for TransCon CNP in Achondroplasia. 11 Nov 2020 Ascendis Pharma in collaboration with VISEN Pharmaceuticals files an IND application with the National Medical Products Administration in China for Achondroplasia prior to November 2020 Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others COPENHAGEN, Denmark, June 11, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) notified the Company that information the Company submitted in connection with the FDA's.

Endocrinology - Ascendis Pharma U

Ascendis Pharma (ASND) In a report released today, Michelle Gilson from Canaccord Genuity maintained a Buy rating on Ascendis Pharma, with a price target of $196.00. The company's shares closed last Friday at $130.25. According to TipRanks.com, Gilson is a 4-star analyst with an average return of 12.6% and a 43.7% success rate Then Ascendis Pharma is committed to supporting your professional development on our journey.Ascendis Pharma is looking to hire an experienced Senior Medical Director, Oncology to join our team. This is an exciting opportunity to join a rapidly growing, innovative company!Position DescriptionThe successful candidate will be the clinical lead of. Ascendis Pharma A/S (NASDAQ:ASND) Q4 2019 Earnings Call Apr 1, 2020, 4:30 p.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Ladies and.

brief-ascendis reports q1 loss per share of eur 1.32 * ascendis pharma - on track for filing u.s. bla for transcon hgh in q2, advancing marketing authorisation application in europe to q COPENHAGEN, Denmark, June 11, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma, Inc. (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) notified the Company that information the Company submitted in connection with the FDA's. The Relative Strength (RS) Rating for Ascendis Pharma climbed into a new percentile Monday, with a rise from 77 to 81.. X When you're researching the best stocks to buy and watch, keep a close on.

Ascendis Pharma A/S Announces Extension of U

  1. Ascendis Pharma A/S Announces First Quarter 2021 Financial Results and Business Update Conference Call on May 27 COPENHAGEN, Denmark, May 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will hold a.
  2. Ascendis Pharma has a target action date of June 25 for its BLA of TransCon hGH (lonapegsomatropin) for the treatment of pediatric Growth Hormone Deficiency (GHD). The drug is designed to release somatropin with the same action and distribution as once-a-day somatropin products, but with a once-a-week injection
  3. Ascendis Pharma AS [ASND] Reports for Purchase. Showing records 1 - 20 ( 161 total ) Company: Ascendis Pharma AS Industry: Medical - Biomedical and Genetics. Record: 1. 06/29/2021

Ascendis Pharma A/S Receives Orphan Designation for

ascendis pharm

Ascendi

Ascendis Pharma (ASND) Bank of America Merrill Lynch 2017Ascendis | Business units | Animal HealthClara - Beyond AchondroplasiaExtensive Modeling-Based Bone Formation After 2 Months ofVersartis: Expect Growth Ahead - Versartis, Inc